{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T15:56:55Z","timestamp":1723046215589},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,3,22]],"date-time":"2010-03-22T00:00:00Z","timestamp":1269216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2010,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gemtuzumab ozogamicin (GO) is a humanized anti\u2010CD33 antibody used for treating patients with CD33+ acute myeloid leukemia (AML). We report three young children (two infants and one toddler) with AML treated with GO 9\u2009mg\/m<jats:sup>2<\/jats:sup>. Two received two doses at diagnosis alone with conventional chemotherapy and one received one dose after relapse. GO was well tolerated and all three achieved remission. All were transplanted: one relapsed after 5 months and died of disease, one died a toxic death in remission due to pulmonary fibrosis, and one survived (41 months from diagnosis). In conclusion, GO was well tolerated in these young patients with evidence for efficacy. Pediatr Blood Cancer 2010;55:183\u2013185. \u00a9 2010 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/pbc.22404","type":"journal-article","created":{"date-parts":[[2010,3,22]],"date-time":"2010-03-22T22:46:32Z","timestamp":1269297992000},"page":"183-185","source":"Crossref","is-referenced-by-count":5,"title":["Upfront use of gemtuzumab ozogamicin in young children with CD33\u2010positive AML"],"prefix":"10.1002","volume":"55","author":[{"given":"Dror","family":"Sayar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoav","family":"Burstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bela","family":"Bielorai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amos","family":"Toren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Dvir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,3,22]]},"reference":[{"key":"e_1_2_4_2_2","first-page":"1490","article-title":"Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross PF","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_4_3_2","first-page":"762","article-title":"Biology and treatment of infant leukemias","volume":"9","author":"Pui CH","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116978"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.72.355"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20599"},{"key":"e_1_2_4_7_2","first-page":"952","article-title":"Prognostic factors in the acute lymphoid and myeloid leukemias of infants","volume":"10","author":"Pui CH","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_4_8_2","first-page":"1303","article-title":"Frequency and clinical significance of the MLL gene rearrangements in infant leukemia","volume":"10","author":"Taki T","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_4_9_2","first-page":"3336","article-title":"Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibody","volume":"53","author":"Hinman LM","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_4_10_2","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody\u2010targeted chemotherapy: A phase I study of an anti\u2010CD33 calicheamicin immunoconjugate","volume":"11","author":"Sievers EL","year":"1999","journal-title":"Blood"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(84)90001-8"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.4.1048.1048"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-1947"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3821"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-172"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208711"},{"key":"e_1_2_4_17_2","first-page":"112","article-title":"AML BFM Study Group prognostic relevance of risk groups in pediatric AML\u2010BFM trials 93 and 98","author":"Creutzig V","year":"2004","journal-title":"Ann Hematol"},{"key":"e_1_2_4_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050512"},{"key":"e_1_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401622"},{"key":"e_1_2_4_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-084293"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22404","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.22404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T00:22:59Z","timestamp":1696724579000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.22404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,22]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,7,15]]}},"alternative-id":["10.1002\/pbc.22404"],"URL":"https:\/\/doi.org\/10.1002\/pbc.22404","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,22]]}}}